Research ExplorerPublicationsUnanswered questions in prostate cancer - findings of an int...

Unanswered questions in prostate cancer - findings of an international multi-stakeholder consensus by the PIONEER consortium

Standard

Unanswered questions in prostate cancer - findings of an international multi-stakeholder consensus by the PIONEER consortium. / Omar, Muhammad Imran; MacLennan, Steven; Ribal, Maria J; Roobol, Monique J; Dimitropoulos, Konstantinos; van den Broeck, Thomas; MacLennan, Sara J; Axelsson, Susan Evans; Gandaglia, Giorgio; Willemse, Peter-Paul; Mastris, Ken; Ransohoff, John Butler; Devecseri, Zsuzsanna; Abbott, Thomas; De Meulder, Bertrand; Bjartell, Anders; Asiimwe, Alex; N'Dow, James; PIONEER Consortium.

In: NAT REV UROL, Vol. 20, No. 8, 08.2023, p. 494-501.

Research output: SCORING: Contribution to journal › Guideline, recommendation, statement › Research › peer-review

Harvard

Omar, MI, MacLennan, S, Ribal, MJ, Roobol, MJ, Dimitropoulos, K, van den Broeck, T, MacLennan, SJ, Axelsson, SE, Gandaglia, G, Willemse, P-P, Mastris, K, Ransohoff, JB, Devecseri, Z, Abbott, T, De Meulder, B, Bjartell, A, Asiimwe, A, N'Dow, J & PIONEER Consortium 2023, 'Unanswered questions in prostate cancer - findings of an international multi-stakeholder consensus by the PIONEER consortium', NAT REV UROL, vol. 20, no. 8, pp. 494-501. https://doi.org/10.1038/s41585-023-00748-9

APA

Omar, M. I., MacLennan, S., Ribal, M. J., Roobol, M. J., Dimitropoulos, K., van den Broeck, T., MacLennan, S. J., Axelsson, S. E., Gandaglia, G., Willemse, P-P., Mastris, K., Ransohoff, J. B., Devecseri, Z., Abbott, T., De Meulder, B., Bjartell, A., Asiimwe, A., N'Dow, J., & PIONEER Consortium (2023). Unanswered questions in prostate cancer - findings of an international multi-stakeholder consensus by the PIONEER consortium. NAT REV UROL, 20(8), 494-501. https://doi.org/10.1038/s41585-023-00748-9

Vancouver

Omar MI, MacLennan S, Ribal MJ, Roobol MJ, Dimitropoulos K, van den Broeck T et al. Unanswered questions in prostate cancer - findings of an international multi-stakeholder consensus by the PIONEER consortium. NAT REV UROL. 2023 Aug;20(8):494-501. https://doi.org/10.1038/s41585-023-00748-9

Bibtex

@article{370f9973506143d5a316d5c8bbe51018,
title = "Unanswered questions in prostate cancer - findings of an international multi-stakeholder consensus by the PIONEER consortium",
abstract = "PIONEER is a European network of excellence for big data in prostate cancer consisting of 37 private and public stakeholders from 9 countries across Europe. Many progresses have been done in prostate cancer management, but unanswered questions in the field still exist, and big data could help to answer these questions. The PIONEER consortium conducted a two-round modified Delphi survey aiming at building consensus between two stakeholder groups - health-care professionals and patients with prostate cancer - about the most important questions in the field of prostate cancer to be answered using big data. Respondents were asked to consider what would be the effect of answering the proposed questions on improving diagnosis and treatment outcomes for patients with prostate cancer and to score these questions on a scale of 1 (not important) to 9 (critically important). The mean percentage of participants who scored each of the proposed questions as critically important was calculated across the two stakeholder groups and used to rank the questions and identify the highest scoring questions in the critically important category. The identification of questions in prostate cancer that are important to various stakeholders will help the PIONEER consortium to provide answers to these questions to improve the clinical care of patients with prostate cancer.",
keywords = "Male, Humans, Consensus, Prostatic Neoplasms/diagnosis, Treatment Outcome, Europe",
author = "Omar, {Muhammad Imran} and Steven MacLennan and Ribal, {Maria J} and Roobol, {Monique J} and Konstantinos Dimitropoulos and {van den Broeck}, Thomas and MacLennan, {Sara J} and Axelsson, {Susan Evans} and Giorgio Gandaglia and Peter-Paul Willemse and Ken Mastris and Ransohoff, {John Butler} and Zsuzsanna Devecseri and Thomas Abbott and {De Meulder}, Bertrand and Anders Bjartell and Alex Asiimwe and James N'Dow and {PIONEER Consortium} and Derya Tilki",
note = "{\textcopyright} 2023. Springer Nature Limited.",
year = "2023",
month = aug,
doi = "10.1038/s41585-023-00748-9",
language = "English",
volume = "20",
pages = "494--501",
journal = "NAT REV UROL",
issn = "1759-4812",
publisher = "NATURE PUBLISHING GROUP",
number = "8",

}

RIS

TY - JOUR

T1 - Unanswered questions in prostate cancer - findings of an international multi-stakeholder consensus by the PIONEER consortium

AU - Omar, Muhammad Imran

AU - MacLennan, Steven

AU - Ribal, Maria J

AU - Roobol, Monique J

AU - Dimitropoulos, Konstantinos

AU - van den Broeck, Thomas

AU - MacLennan, Sara J

AU - Axelsson, Susan Evans

AU - Gandaglia, Giorgio

AU - Willemse, Peter-Paul

AU - Mastris, Ken

AU - Ransohoff, John Butler

AU - Devecseri, Zsuzsanna

AU - Abbott, Thomas

AU - De Meulder, Bertrand

AU - Bjartell, Anders

AU - Asiimwe, Alex

AU - N'Dow, James

AU - PIONEER Consortium

AU - Tilki, Derya

N1 - © 2023. Springer Nature Limited.

PY - 2023/8

Y1 - 2023/8

N2 - PIONEER is a European network of excellence for big data in prostate cancer consisting of 37 private and public stakeholders from 9 countries across Europe. Many progresses have been done in prostate cancer management, but unanswered questions in the field still exist, and big data could help to answer these questions. The PIONEER consortium conducted a two-round modified Delphi survey aiming at building consensus between two stakeholder groups - health-care professionals and patients with prostate cancer - about the most important questions in the field of prostate cancer to be answered using big data. Respondents were asked to consider what would be the effect of answering the proposed questions on improving diagnosis and treatment outcomes for patients with prostate cancer and to score these questions on a scale of 1 (not important) to 9 (critically important). The mean percentage of participants who scored each of the proposed questions as critically important was calculated across the two stakeholder groups and used to rank the questions and identify the highest scoring questions in the critically important category. The identification of questions in prostate cancer that are important to various stakeholders will help the PIONEER consortium to provide answers to these questions to improve the clinical care of patients with prostate cancer.

AB - PIONEER is a European network of excellence for big data in prostate cancer consisting of 37 private and public stakeholders from 9 countries across Europe. Many progresses have been done in prostate cancer management, but unanswered questions in the field still exist, and big data could help to answer these questions. The PIONEER consortium conducted a two-round modified Delphi survey aiming at building consensus between two stakeholder groups - health-care professionals and patients with prostate cancer - about the most important questions in the field of prostate cancer to be answered using big data. Respondents were asked to consider what would be the effect of answering the proposed questions on improving diagnosis and treatment outcomes for patients with prostate cancer and to score these questions on a scale of 1 (not important) to 9 (critically important). The mean percentage of participants who scored each of the proposed questions as critically important was calculated across the two stakeholder groups and used to rank the questions and identify the highest scoring questions in the critically important category. The identification of questions in prostate cancer that are important to various stakeholders will help the PIONEER consortium to provide answers to these questions to improve the clinical care of patients with prostate cancer.

KW - Male

KW - Humans

KW - Consensus

KW - Prostatic Neoplasms/diagnosis

KW - Treatment Outcome

KW - Europe

U2 - 10.1038/s41585-023-00748-9

DO - 10.1038/s41585-023-00748-9

M3 - Guideline, recommendation, statement

C2 - 37012441

VL - 20

SP - 494

EP - 501

JO - NAT REV UROL

JF - NAT REV UROL

SN - 1759-4812

IS - 8

ER -